Aldesleukin (Recombinant interleukin-2). A review of its pharmacological properties, clinical efficacy and tolerability in patients with renal cell carcinoma (vol 7, pg 285, 1997)

被引：0
|
作者：
Jeal, W
Goa, KL
机构：
来源：
BIODRUGS | 1997年 / 8卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：192 / 192
页数：1
相关论文
共 50 条
  • [41] PHASE-II STUDY OF CONTINUOUS INTRAVENOUS-INFUSION OF RECOMBINANT INTERLEUKIN-2 IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA
    LOPEZ, M
    CARPANO, S
    CANCRINI, A
    MARCELLINI, M
    DELMEDICO, P
    RINALDI, M
    VICI, P
    PAOLETTI, G
    DILAURO, L
    ANNALS OF ONCOLOGY, 1993, 4 (08) : 689 - 691
  • [42] INTERLEUKIN-2 DOSE, BLOOD MONOCYTE AND CD25+ LYMPHOCYTE COUNTS AS PREDICTORS OF CLINICAL-RESPONSE TO INTERLEUKIN-2 THERAPY IN PATIENTS WITH RENAL-CELL CARCINOMA
    HERMANN, GG
    GEERTSEN, PF
    VONDERMAASE, H
    ZEUTHEN, J
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1991, 34 (02) : 111 - 114
  • [43] Efficacy and tolerability of high dose interleukin-2 (HD IL-2) after disease progression on targeted therapy (TT) for metastatic renal cell carcinoma (mRCC).
    Vu, Peter
    Mai, Hanh P.
    Adams, William
    Gonzalez, Beverly
    Kliethermes, Stephanie
    Clark, Joseph
    Henry, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [44] CLINICAL-RESULTS AND CHARACTERIZATION OF TUMOR-INFILTRATING LYMPHOCYTES WITH OR WITHOUT RECOMBINANT INTERLEUKIN-2 IN HUMAN METASTATIC RENAL-CELL CARCINOMA
    BUKOWSKI, RM
    SHARFMAN, W
    MURTHY, S
    RAYMAN, P
    TUBBS, R
    ALEXANDER, J
    BUDD, GT
    SERGI, JS
    BAUER, L
    GIBSON, V
    STANLEY, J
    BOYETT, J
    PONTES, E
    FINKE, J
    CANCER RESEARCH, 1991, 51 (16) : 4199 - 4205
  • [45] Retrospective Analysis of the Safety and Efficacy of High-dose Interleukin-2 After Prior Tyrosine Kinase Inhibitor Therapy in Patients with Advanced Renal Cell Carcinoma (vol 37, pg 360, 2014)
    Lam, E. T.
    Wong, M. K.
    Agarwal, N.
    JOURNAL OF IMMUNOTHERAPY, 2014, 37 (09) : 468 - 468
  • [46] Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability (vol 44, pg 197, 1997)
    Belli, F
    Arienti, F
    SuleSuso, J
    Clemente, C
    Mascheroni, L
    Cattelan, A
    Santantonio, C
    Gallino, GF
    Melani, C
    Rao, S
    Colombo, MP
    Maio, M
    Cascinelli, N
    Parmiani, G
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1997, 45 (02) : 119 - 119
  • [47] Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma (vol 7, pg 1815, 2021)
    Hirsch, L.
    Chanza, Martinez N.
    Farah, S.
    JAMA ONCOLOGY, 2021, 7 (12) : 1904 - 1904
  • [48] Clinical and Immunologic Effects of Intranodal Autologous Tumor Lysate-Dendritic Cell Vaccine with Aldesleukin (Interleukin 2) and IFN-α2a Therapy in Metastatic Renal Cell Carcinoma Patients
    Schwaab, Thomas
    Schwarzer, Adrian
    Wolf, Benita
    Crocenzi, Todd S.
    Seigne, John D.
    Crosby, Nancy A.
    Cole, Bernard F.
    Fisher, Jan L.
    Uhlenhake, Jill C.
    Mellinger, Diane
    Foster, Cathy
    Szczepiorkowski, Zbigniew M.
    Webber, Susan M.
    Schned, Alan R.
    Harris, Robert D.
    Barth, Richard J., Jr.
    Heaney, John A.
    Noelle, Randolph J.
    Ernstoff, Marc S.
    CLINICAL CANCER RESEARCH, 2009, 15 (15) : 4986 - 4992
  • [49] PROGNOSTIC FACTORS OF THE CLINICAL-RESPONSE TO SUBCUTANEOUS IMMUNOTHERAPY WITH INTERLEUKIN-2 ALONE IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA
    LISSONI, P
    BARNI, S
    ARDIZZOIA, A
    CRISPINO, S
    PAOLOROSSI, F
    ANDRES, M
    SCARDINO, E
    TANCINI, G
    ONCOLOGY, 1994, 51 (01) : 59 - 62
  • [50] Clinical and Safety Profile of High-Dose Interleukin-2 Treatment in Elderly Patients with Metastatic Melanoma and Renal Cell Carcinoma
    Clark, James M.
    Kelley, Benjamin
    Titze, Jill
    Fung, Henry
    Maciejewski, John
    Nathan, Sunita
    Rich, Elizabeth
    Basu, Sanjib
    Kaufman, Howard L.
    ONCOLOGY, 2013, 84 (02) : 123 - 126
12345